AU2006249479A1 - Lipid construct for delivery of interferon to a mammal - Google Patents

Lipid construct for delivery of interferon to a mammal Download PDF

Info

Publication number
AU2006249479A1
AU2006249479A1 AU2006249479A AU2006249479A AU2006249479A1 AU 2006249479 A1 AU2006249479 A1 AU 2006249479A1 AU 2006249479 A AU2006249479 A AU 2006249479A AU 2006249479 A AU2006249479 A AU 2006249479A AU 2006249479 A1 AU2006249479 A1 AU 2006249479A1
Authority
AU
Australia
Prior art keywords
interferon
lipid
construct
biotin
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006249479A
Other languages
English (en)
Inventor
W. Blair Geho
John R. Lau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SDG Technology Inc
Original Assignee
SDG Technology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/384,575 external-priority patent/US20070218117A1/en
Application filed by SDG Technology Inc filed Critical SDG Technology Inc
Publication of AU2006249479A1 publication Critical patent/AU2006249479A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dispersion Chemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2006249479A 2005-05-23 2006-05-16 Lipid construct for delivery of interferon to a mammal Abandoned AU2006249479A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US68387805P 2005-05-23 2005-05-23
US60/683,878 2005-05-23
US11/384,575 US20070218117A1 (en) 2006-03-20 2006-03-20 Supra molecular construct for delivery of interferon to a mammal
US11/384,575 2006-03-20
PCT/US2006/019118 WO2006127360A2 (en) 2005-05-23 2006-05-16 Lipid construct for delivery of interferon to a mammal

Publications (1)

Publication Number Publication Date
AU2006249479A1 true AU2006249479A1 (en) 2006-11-30

Family

ID=37452604

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006249479A Abandoned AU2006249479A1 (en) 2005-05-23 2006-05-16 Lipid construct for delivery of interferon to a mammal

Country Status (6)

Country Link
EP (1) EP1883395A4 (enExample)
JP (1) JP2008542270A (enExample)
KR (1) KR20080042045A (enExample)
AU (1) AU2006249479A1 (enExample)
CA (1) CA2609376A1 (enExample)
WO (1) WO2006127360A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008286240B2 (en) * 2007-08-03 2013-05-23 Biotron Limited Hepatitis C antiviral compositions and methods
US8962015B2 (en) * 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
BRPI0820791A2 (pt) * 2007-12-17 2015-06-16 Lux Innovate Ltd Composições e métodos para manutenção de sistemas de condução e contenção de fluido
AU2013337702A1 (en) 2012-11-02 2015-05-21 Merck Patent Gmbh Method of reducing adverse effects in a cancer patient undergoing treatment with a MEK inhibitor
CN111690539A (zh) * 2020-07-07 2020-09-22 安徽农业大学 高效秸秆纤维素分解菌的筛选及应用
WO2022114908A1 (ko) * 2020-11-27 2022-06-02 (주)디앤디파마텍 비오틴 모이어티, 지방산 모이어티 또는 이의 조합이 결합된 생리활성 물질 접합체의 경구 제형
GB2617717A (en) * 2020-11-27 2023-10-18 D&D Pharmatech Inc Biologically active material conjugate having biotin moiety, fatty acid moiety, or combination thereof coupled thereto

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603044A (en) * 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
GB9426484D0 (en) * 1994-12-08 1995-03-08 Ciba Geigy Ag Compositions
TW520297B (en) * 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method

Also Published As

Publication number Publication date
CA2609376A1 (en) 2006-11-30
EP1883395A4 (en) 2012-07-04
EP1883395A2 (en) 2008-02-06
WO2006127360A3 (en) 2008-01-10
JP2008542270A (ja) 2008-11-27
WO2006127360A2 (en) 2006-11-30
KR20080042045A (ko) 2008-05-14

Similar Documents

Publication Publication Date Title
DK2859015T3 (en) LIGANDS MODIFIED BY CIRCULAR MODIFICATION AS AGONISTS AND ANTAGONISTS
EP2205217B1 (en) Orally bioavailable lipid-based constructs
US8257735B2 (en) Method of increasing the bioavailability of recombinant human insulin isophane in a patient
US10463616B2 (en) Lipid construct for delivery of insulin to a mammal
EP3391876B1 (en) Lipid construct for delivery of insulin to a mammal
US7871641B2 (en) Hepatocyte-targeting vehicle for delivery of glargine insulin to a mammal
AU2006249479A1 (en) Lipid construct for delivery of interferon to a mammal
US20070218117A1 (en) Supra molecular construct for delivery of interferon to a mammal
US20100129428A1 (en) Supra molecular construct for delivery of interferon to a mammal
US20220110870A1 (en) Lipid construct for delivery of insulin to a mammal
AU2012247063B2 (en) Lipid construct for delivery of insulin to a mammal
CA2864366C (en) Lipid construct comprising an amphipathic lipid, cholesterol, dicetyl phosphate, and a hepatocyte receptor binding molecule
DK1883394T3 (en) Lipid construct for delivering insulin to a mammal
AU2015249189A1 (en) Lipid construct for delivery of insulin to a mammal
HK1262603B (en) Lipid construct for delivery of insulin to a mammal
HK1262603A1 (en) Lipid construct for delivery of insulin to a mammal
HK1116396B (en) Lipid construct for delivery of insulin to a mammal
HK1116396A (en) Lipid construct for delivery of insulin to a mammal
HK1259503A1 (en) Orally bioavailable lipid-based constructs

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application